高级检索
当前位置: 首页 > 详情页

瑞戈非尼用于用过索拉非尼治疗的肝细胞癌患者临床试验

| 认领 | |

文献详情

编号/登记号:
注册时间:
项目类型:
本院角色:
多中心研究:
参与国家:
招募状态:
试验分期:
研究疾病/适应症:
研究设计:
研究类型:
药物名称:
药物类型:
伦理委员会审批: 批准本研究的伦理委员会名称: 伦理委员会审批时间:
研究负责人:
研究参与人:
研究单位: [1]BCLC Group. Liver Unit Hospital Clinic,University of Barcelona,DIBAPS [2]Hospital Clínic i Provincial de Barcelona [3]Royal Brisbane and Women's Hospital [4]Royal Prince Alfred Hospital [5]Liverpool Hospital [6]Monash Medical Centre [7]Eastern Health [8]CH de Jolimont - Lobbes Site de Jolimont [9]UZ Brussel [10]Irmandade Santa Casa de Misericordia de Porto Alegre [11]Clinica AMO [12]Instituto COI de Educa??o e Pesquisa [13]Hospital das Clínicas da Faculdade de Medicina da USP [14]Hospital Sirio Libanes [15]Centre Hospitalier Universitaire Brabois [16]Hospital Claude Huriez - Lille [17]Hospital Arche - Nice [18]Hospital Beaujon - Clichy [19]Centre Hospitalier Universitaire - Angers [20]Hospital Henri Mondor - Créteil [21]Hotel Dieu - Lyon Cedex [22]Centre Eugène Marquis - Rennes Cedex? [23]Hospital Tenon - Paris [24]CHRU Cote de Nacre [25]CHU ESTAING [26]Institut Gustave Roussy - Villejuif [27]Hospital Purpan - Toulouse [28]Hospital du Bocage - Dijon [29]Hospital Saint-Eloi - Montpellier Cedex [30]Hospital de la Timone - Marseille [31]Hopital de la Conception - Marseille [32]Johannes-Gutenberg-Universit?t Mainz [33]Klinikum Esslingen GmbH [34]University tskliniken des Saarlandes [35]University tsklinikum Otto-von Guericke - Magdeburg [36]Kliniken Essen - Mitte [37]University tsklinikum Hamburg Eppendorf (UKE) [38]LMU Klinikum der Universit?t München - Gro?hadern [39]Klinikum der Johann Wolfgang Goethe Universit?t Frankfurt [40]University tsklinikum Heidelberg [41]Charité Campus Virchow-Klinikum (CVK) [42]University tsklinikum Aachen [43]Kliniken der Medizinischen Hochschule Hannove [44]Universitytsklinikum Koln [45]Caritas Krankenhaus GmbH [46]Fovarosi Szent Laszlo Korhaz [47]University of Debrecen Medical&Health Science Center [48]Csolnoky Ferenc Veszprem County Hospital [49]Kaposi Mor Teaching Hospital of Somogy County [50]IRCCS Istituto Clinico Humanitas [51]A.O.U. Policlinico Paolo Giaccone [52]A.O.U. di Bologna [53]A.O.U. Maggiore della Carità [54]Università Cattolica del Sacro Cuore [55]A.O.U. Pisana [56]A.O.R.N. Antonio Cardarelli [57]A.O.U. di Modena Policlinico [58]IRCCS INT Fondazione Pascale [59]IRCCS Casa Sollievo Sofferenza [60]A.O. Papa Giovanni XXIII [61]IRCCS Istituto Oncologico Veneto - IOV [62]A.O.U. Integrata Verona [63]A.O.U. Seconda Università [64]IRCCS A.O. Saverio de Bellis [65]A.O. Osp Niguarda Ca' Granda [66]A.O. Giuseppe Brotzu [67]IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico [68]IRCCS A.O.U. San Martino – IST Ist. Nazionale Ricerca Cancro [69]Università Cattolica del Sacro Cuore [70]ISMETT Ist Mediterraneo Trapianti e Terapie alta spec [71]A.O. Città della Salute e della Scienza di Torino [72]Kinki University Hospital [73]National Cancer Center Hospital East [74]National Cancer Center Hospital [75]Chiba University Hospital [76]Musashino Red Cross Hospital [77]Osaka Medical Center for Cancer and Cardiovascular Diseases [78]Kyushu Medical Center [79]Pusan National University Hospital [80]Seoul National University Hospital [81]Kyungpook National University Hospital [82]Seoul National University Hospital [83]Erasmus Medisch Centrum [84]Academisch Medisch Centrum Universiteit van Amsterdam [85]Leids Universitair Medisch Centrum [86]Russian Oncological Scientific Center n.a. N.N. Blokhin RAMS [87]Altay Oncological Dispensary [88]Russian Scientific Surgery Centre n.a. Academician B.V.Petro [89]Russian Research Oncology Centre n.a. N.N Blokhin of RAMS [90]St. Petersburg State Medical Academy named after Mechnikov [91]Singapore Oncology Consultations [92]National University Hospital [93]Hospital Clínico Universitario de Santiago de Compostela [94]Hospital Central de Asturias [95]Ciutat Sanitària i Universitaria de la Vall d'Hebron [96]Hospital Ramón y Cajal [97]Hospital Reina Sofía [98]Hospital General Universitario de Alicante [99]Hospital General Universitario Gregorio Mara?ón [100]Hospital Clínico Universitario Lozano Blesa [101]Hospital del Rio Hortega [102]Centro Integral Oncológico Clara Campal [103]Hospital Universitario 12 de Octubre [104]Kantonsspital St. Gallen [105]Inselspital Bern [106]Dott. med. Piercarlo Saletti. Vice-primario [107]Kings College Hospital [108]Bristol Haematology & Oncology Centre [109]University of Birmingham [110]St James' University Hospital [111]National Taiwan University Hospital [112]Veterans General Hospital [113]Chang Gung Memorial Hospital at Linkou [114]Chang Gung Memorial Hospital Kaohsiung [115]Hunter Holmes McGuire Veterans Affairs Medical Center [116]Mount Sinai Medical Center [117]University of Louisville [118]Bellevue Hospital Center [119]University of Minnesota [120]University of Florida Health Sciences Center [121]Florida Hospital Orlando [122]Washington University School of Medicine [123]University of Rochester Medical Center [124]Ronald Reagan UCLA Medical Center [125]Georgetown University Medical Center [126]Barbara Ann Karmanos Cancer Institute [127]University of Colorado [128]Cedars- Sinai Medical Center [129]Oregon Health and Science University [130]University of Pittsburgh Medical Center Health System [131]University of Massachusetts Memorial Medical Center [132]University of Texas Southwestern Medical Center [133]Tufts Medical Center [134]UC Irvine Medical Center [135]University of Chicago [136]University of Pittsburgh Medical Center Health System [137]Virginia Mason Medical Center [138]Tampa General Medical Group [139]解放军第八一医院 [140]复旦大学附属中山医院 [141]西安交通大学医学院附属第一医院 [142]大连医科大学附属第一医院 [143]上海交通大学医学院附属仁济医院 [144]上海东方肝胆外科医院 [145]第四军医大学附属第一医院 [146]北京肿瘤医院 [147]安徽医科大学附属第一医院 [148]中国解放军307医院 [149]吉林省肿瘤医院 [150]天津医科大学附属肿瘤医院 [151]广西医科大学附属肿瘤医院 [152]中南大学湘雅三院 [153]哈尔滨医科大学附属肿瘤医院 [154]第四军医大学附属唐都医院 [155]四川大学华西医院 [156]南京军区福州总院 [157]北京肿瘤医院 [158]广东省人民医院 [159]第三军医大学附属西南医院 [160]南方医院 [161]复旦大学附属肿瘤医院 [162]中国人民解放军第302医院 [163]华中科技大学同济医学院附属同济医院 [164]苏州大学附属第一医院 [165]首都医科大学附属佑安医院 [166]安徽医科大学附属第一医院 [167]中山大学肿瘤医院

研究目的:
评估 Regorafenib 在索拉非尼治疗之后疾病进展的 HCC 患者中的疗效和安全性。约有 530 名符合入选标准的患者将按 2:1 的比例被随机分配至瑞戈非尼组和安慰剂组(1/3机会接受安慰剂治疗)。这项研究的主要终点是总生存期。

资源点击量:428 今日访问量:1 总访问量:411 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)